The epidermal growth factor receptor (EGFR) is upregulated in numerous human cancers. Inhibition of EGFR signaling induces autophagy in tumor cells. Here, we report an unanticipated role for the inactive EGFR in autophagy initiation. Inactive EGFR interacts with the oncoprotein LAPTM4B that is required for the endosomal accumulation of EGFR upon serum starvation. Inactive EGFR and LAPTM4B stabilize each other at endosomes and recruit the exocyst subcomplex containing Sec5. We show that inactive EGFR, LAPTM4B, and the Sec5 subcomplex are required for basal and starvation-induced autophagy. LAPTM4B and Sec5 promote EGFR association with the autophagy inhibitor Rubicon, which in turn disassociates Beclin 1 from Rubicon to initiate autophagy. Thus, the oncoprotein LAPTM4B facilitates the role of inactive EGFR in autophagy initiation. This pathway is positioned to control tumor metabolism and promote tumor cell survival upon serum deprivation or metabolic stress.
INTRODUCTION
Autophagy (macroautophagy) is a self-eating process by which part of the cytoplasm, organelles, and/or membrane are engulfed and eventually digested in lysosomes for cell homeostasis, development, and/or nutrient recycling (Feng et al., 2014) . Autophagy is inducible by nutrient starvation as a mechanism to protect cells (Klionsky et al., 2012) . The core machinery required for autophagosome formation consists of autophagyrelated (Atg) proteins that function in a specific order (Feng et al., 2014) . The Beclin 1 (Atg6 in yeast) complex containing Beclin 1, VPS34, ATG14, and VPS15 plays essential roles in phagophore nucleation and autophagy initiation and is emerging as a regulatory complex by autophagy signals (He and Levine, 2010; Matsunaga et al., 2009; Sun et al., 2009; Zhong et al., 2009) . LC3 (Atg8 in yeast) is an autophagy regulator downstream of Beclin 1, and a hallmark of autophagosome formation is the conversion of the cytosolic LC3-I into the lipidated LC3-II that associates with autophagosome membranes (Kabeya et al., 2000) . The exocyst also plays a role in the Beclin 1 complex assembly during autophagy initiation (Bodemann et al., 2011) , but how and where the exocyst and the autophagy complexes are regulated is not defined.
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that plays fundamental roles in physiology and cancers (Schlessinger, 2000) . Aberrant EGFR signaling due to EGFR mutations and/or protein overexpression is associated with most epithelial cancers (Mendelsohn and Baselga, 2006) . Recent studies have shown a role for EGFR signaling in autophagy suppression by activation of the PI3K/AKT/mTOR pathway or by EGFR-mediated phosphorylation and inhibition of Beclin 1 (Wei et al., 2013) . Autophagy is generally thought to prevent cancer initiation but is also positioned to promote cancer cell survival upon metabolic stress (Brech et al., 2009; White, 2012) . Rapamycin, an autophagy inducer, exhibits cytotoxic effects in cancer cells treated with EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib (Fung et al., 2012; Gorzalczany et al., 2011) . However, autophagy induced by EGFR TKIs or neutralizing antibody shows cytoprotective roles (Choi et al., 2013; Dragowska et al., 2013; Eimer et al., 2011; Han et al., 2011; Li and Fan, 2010; Li et al., 2010b; Sobhakumari et al., 2013; Zou et al., 2013) , suggesting that EGFR TKIs (or neutralizing antibody) may induce autophagy by a mechanism distinct from rapamycin. At least some EGFR-overexpressing cells and tumors are dependent on autophagy for growth and survival (Jutten et al., 2013; Jutten and Rouschop, 2014) . A gefitinib-resistant subpopulation of lung adenocarcinoma cells depend on enhanced autophagic activity, but not on EGFR signaling, for survival (Sakuma et al., 2013) . The combined data suggest a kinase-independent role for EGFR in autophagy that regulates cancer cell survival.
The lysosomal-associated transmembrane protein 4B (LAPTM4B) is a tetratransmembrane protein localized primarily to the late endosome and lysosome (Liu et al., 2004) . LAPTM4B was originally identified in hepatocellular carcinoma patients as an abnormally overexpressed protein and was later found to be upregulated in many other human cancers, including breast, lung, ovarian, and colon cancers (Kasper et al., 2005) . Ectopic expression of LAPTM4B transforms normal cells and promotes proliferation, migration, and invasion of cancer cells (Li et al., 2011a; Yang et al., 2010) . LAPTM4B is proposed to promote cancer cell proliferation by upregulating PI3K/ATK signaling (Li et al., 2010a) . We have shown that LAPTM4B blocks EGF-stimulated EGFR intraluminal sorting and lysosomal degradation, resulting in enhanced and prolonged EGFR signaling (X.T., Y.S., N.T., Y. Liao, A.C. Hedman, and R.A.A., unpublished data). A potential role for LAPTM4B in the promotion or inhibition Figure 1 . EGFR, but Not Its Kinase Activity, Is Required for Autophagy (A) Knockdown of EGFR inhibits basal and serum starvation-induced LC3-II (autophagosome marker) turnover in MDA-MB-231 cells. Cells transfected with indicated siRNAs were cultured in normal medium (N) or serum-free starvation medium (S) for 24 hr and then were treated with 80 mM chloroquine (CQ) for 2 hr to induce LC3-II accumulation. Whole-cell lysates were harvested for western blot analysis of LC3-II.
of autophagosome maturation has been proposed (Li et al., 2011b; Vergarajauregui et al., 2011) .
Here, we report an unexpected role for inactive EGFR in autophagy initiation. Upon serum starvation, inactive EGFR collaborates with LAPTM4B and Sec5 at endosomes to disassociate Rubicon from Beclin 1, which in turn initiates autophagy. EGFR TKIs also induce autophagy initiation, revealing that kinase-inactive EGFR functions in autophagy, and this may be a mechanism for tumor cell resistance to EGFR TKIs.
RESULTS
EGFR, but Not Its Kinase Activity, Is Required for Autophagy EGFR TKIs induce autophagy (Han et al., 2011; Jutten and Rouschop, 2014; Li et al., 2010b) , suggesting a direct role for inactive EGFR in autophagy upregulation. To test this hypothesis, we examined if EGFR is required for autophagic flux. Knockdown of EGFR inhibited basal and serum starvation-induced autophagic flux ( Figure 1A ), as shown by the LC3-II levels, before and after inhibition of its degradation by chloroquine. Two different EGFR small interfering RNAs (siRNAs) independently knocked down EGFR expression and inhibited autophagic flux (Figures 1B and 1C) , and loss of EGFR markedly reduced endogenous LC3 puncta formation ( Figures 1D and 1E) , indicating a role for EGFR in autophagy initiation.
To determine whether the role for EGFR in autophagy is due to its overexpression, we tested the effects of EGFR knockdown in 7 cell lines, four of which do not overexpress EGFR ( Figure S1A available online). Knockdown of EGFR inhibited autophagic flux in each cell line ( Figure S1B ), indicating a role in autophagy independent of receptor level. Importantly, the role for EGFR in autophagy initiation is receptor selective, as loss of PDGFRB, FGFR2, or c-Met did not suppress autophagy (Figures S1C-S1E).
Active EGFR blocks autophagy (Wei et al., 2013) , and we confirmed that EGF stimulation inhibits autophagy initiation (Figure S1F) ; thus, we hypothesized that inactive EGFR initiates autophagy. To test this hypothesis, siRNA-resistant wild-type (WT) or K721A kinase-dead (KD) EGFR was re-expressed in cells in which endogenous EGFR was knocked down. Re-expressed EGFR-WT is autophosphorylated and activates AKT signaling when stimulated with EGF, but EGFR-KD does not autophosphorylate or activate AKT ( Figure S1G ). However, re-expression of either WT or KD EGFR rescued autophagic flux in EGFR knockdown cells ( Figures 1F and 1G , left panels), and treatment of EGFR-WT re-expressing cells with the EGFR TKI gefitinib enhanced the rescue of autophagy initiation ( Figures 1F and  1G , right panels), indicating the role for EGFR in autophagy initiation is kinase independent. Serum starvation induced an increase in GFP-LC3 puncta (autophagosomes) ( Figure S1H ), and loss of EGFR strongly inhibited autophagosome formation ( Figures 1H and 1I ). Re-expression of either WT or KD EGFR fully rescued the starvation-induced formation of GFP-LC3 puncta in EGFR knockdown cells ( Figures 1H and 1I ). These combined results reveal a kinase-independent role for EGFR in basal and serum starvation-induced autophagy.
Starvation Induces Accumulation of Inactive EGFR at LAPTM4B-Positive Endosomes
To explore how inactive EGFR controls autophagy, the subcellular localization of EGFR in normal and serum-starved cells was investigated. We previously showed that LAPTM4B inhibits EGF-stimulated EGFR lysosomal sorting (X.T., Y.S., N.T., Y. Liao, A.C. Hedman, and R.A.A., unpublished data). Here, we show that EGFR partially colocalized with LAPTM4B at endosomes in cells grown with serum (Figure 2A, top) . The specificity of EGFR immunostaining was confirmed by siRNA knockdown of EGFR ( Figure S2A) . Surprisingly, serum-starvation enhanced EGFR accumulation at LAPTM4B-positive endosomes (Figure 2A, bottom) , which include both late and early endosomes ( Figure S2B ). Starvation-induced endosomal EGFR accumulation and EGFR-LAPTM4B colocalization were observed in all cells assayed ( Figures S2C-S2F ). Serum starvation also induced intracellular accumulation of c-Met and FGFR2, and c-Met colocalized well with LAPTM4B but FGFR2 did not ( Figures  S2G-S2J ). However, neither FGFR2 nor c-Met was required for autophagy, indicating that this is an EGFR-selective function ( Figures S1C-S1E) .
EGFR translocates to endosomes upon EGF stimulation and receptor autophosphorylation/activation (Wiley, 2003) . We (B) Knockdown of EGFR by two distinct siRNAs inhibits LC3-II generation. MDA-MB-231 cells were cultured in normal medium. Unless otherwise indicated, the EGFR siRNA #1 was used in all the remaining experiments. (C) Quantification of LC3-II levels in (B) ; mean + SD, n = 3, ***p < 0.001. (D) CQ induces accumulation of LC3 puncta (autophagosomes) in control cells, but not in EGFR knockdown cells. Control or EGFR siRNA-transfected cells in normal medium were pretreated with CQ for 3 hr and fixed for immunostaining of endogenous LC3 (red) and EGFR (green). DAPI was used to stain the nuclei; boxes indicate selected regions for magnified new. Bar, 10 mm. (E) Quantification of LC3 puncta in (D); mean + SD, n = 3, ***p < 0.001. (F) Left: re-expression of wild-type (WT) or the K721A kinase-dead (KD) EGFR rescues LC3-II turnover in EGFR-knockdown cells. Right: gefitinib (2 mM) treatment enhances autophagy rescue by EGFR-WT. siRNA-resistant EGFR-WT or -KD was expressed in MDA-MB-231 cells by lentivirus-mediated infection. Endogenous EGFR was knocked down by siRNA #1, and cells were cultured in normal medium and treated with CQ for 2 hr before whole-cell lysate harvest for western analysis. EV, empty vector. (G) Quantification of LC3-II levels in (F) ; mean + SD, n = 3, **p < 0.01, ***p < 0.001. (H) Representative images of serum starvation-induced EGFP-LC3 puncta in MDA-MB-231 cells treated with indicated siRNAs with or without re-expression of EGFR-WT or EGFR-KD. EGFP-LC3 was expressed by lentivirus infection and a monoclonal cell line stably expressing low levels of EGFP-LC3 was selected. Endogenous EGFR was knocked down by siRNA, and siRNA-resistant WT or KD EGFR was re-expressed using lentivirus. Cells were serum starved and fixed for fluorescence microscopy. Bar, 10 mm. (I) Quantification of the number of EGFP-LC3 puncta in (H); mean + SD, n = 3, ***p < 0.001. See also Figure S1 . (C) The whole-cell lysates with or without serum starvation were analyzed by western blot to detect phosphor-EGFR (Y1068) and total EGFR. Different loadings of the lysates from MDA-MB-231 cells with 5 min EGF (100 ng/ml) stimulation after starvation were used as a standard to quantify phosphor-EGFR levels in cells without EGF stimulation. (D) Quantification of the phosphor-EGFR (Y1068) levels in (C); mean + SD, n = 3. (E) Quantification of endosomal EGFR staining in cells cultured in normal medium, serum-free medium (STV), or serum-free medium plus EGF (100 ng/ml, 15 min), as shown in (B) ; mean + SD, n = 3, **p < 0.01, ***p < 0.001.
(legend continued on next page)
therefore examined whether the EGFR accumulated at LAPTM4B-positive endosomes upon serum starvation was phosphorylated. EGF-stimulated cells were used as positive controls for phospho-EGFR staining, as shown in Figure 2B . Interestingly, in either serum grown or the starved condition, phospho-EGFR was not detected by immunofluorescence, but there was clear endosomal EGFR accumulation ( Figure 2B ). The endosomal staining of EGFR appears stronger than the plasma membrane staining because of the point concentration at endosomes (Figures 2A, 2B , and S2). Quantitative western blotting confirmed that less than 2% of the total EGFR was phosphorylated in cells cultured in either normal or serum starved medium, assuming that 5 min stimulation with 100 ng/ml EGF stimulated maximal EGFR phosphorylation ( Figures 2C and 2D ). Stimulation of cells with 100 ng/ml EGF for 15 min causes endocytosis and accumulation of over 95% of total EGFR at endosomes; we therefore calculated how much of EGFR was accumulated at endosomes in normal and starved cells by quantifying the endosomal EGFR staining in these conditions versus the EGF-stimulated (15 min) condition. This indicated that 20% or 40% of total EGFR is accumulated at endosomes in normal versus serum-starved conditions, respectively (Figures 2E and 2F) . This demonstrates that in serum-grown or starved cells the endosomal EGFR is primarily unphosphorylated. Importantly, upon serum starvation, the amount of endosomal EGFR increased from 20% to 40% ( Figures 2B and 2F ), but the total phospho-EGFR level decreased ( Figures 2C and 2D ), indicating that serum starvation-induced endosomal accumulation of inactive EGFR.
Inactive EGFR and LAPTM4B Interact and Stabilize Each Other at Endosomes
The interaction between EGFR and LAPTM4B was studied to explore the mechanism for EGFR endosomal localization. EGFR was coimmunoprecipitated specifically with LAPTM4B, but not with other LAPTM members ( Figure S3A ). Serum starvation increased EGFR endosomal accumulation ( Figure 2 ) and enhanced the LAPTM4B-EGFR association ( Figure 3A ), whereas EGF stimulation reduced the interaction ( Figure 3B ), indicating that LAPTM4B preferentially interacts with inactive EGFR. This was confirmed using the EGFR-KD mutant that has much stronger interaction with LAPTM4B compared with EGFR-WT (Figure 3C ). EGF stimulation did not affect the LAPTM4B interaction with EGFR-KD ( Figure 3D ) that is not activated by EGF (Figure S1G) . As serum starvation also induces endosomal accumulation of other receptors, LAPTM4B interaction with PDGFRB, FGFR2, and c-Met was tested. These receptors also coimmunoprecipitated with LAPTM4B ( Figure S3B ), but none of these interactions were enhanced upon serum starvation ( Figure S3C ), indicating that the serum starvation promoted EGFR-LAPTM4B interaction is selective.
As LAPTM4B is an endosomal protein (Shao et al., 2003; Vergarajauregui et al., 2011) , we determined whether LAPTM4B could modulate EGFR endosomal accumulation. MDA-MB-231 cells express variable amounts of LAPTM4B, and in cells with low LAPTM4B, there was less endosomal EGFR ( Figure S3D , arrowhead), suggesting LAPTM4B modulation of EGFR localization. Strikingly, upon knockdown of LAPTM4B, EGFR endosomal accumulation was lost, but EGFR targeting was fully rescued by re-expression of siRNA-resistant LAPTM4B ( Figure 3E ). Loss of LAPTM4B also resulted in a loss of endosomal EGFR in A431 and HeLa cells, indicating that this was independent of cell type ( Figures S3E and S3F ). To confirm that LAPTM4B mediates endosomal accumulation of inactive EGFR, cells stably expressing C terminally Flag-tagged WT or KD EGFR were generated. Both WT and KD EGFR had endosomal localization, but this was disrupted by loss of LAPTM4B ( Figure 3F ), demonstrating that LAPTM4B is required for the endosomal accumulation of inactive EGFR. Though c-Met and FGFR2 also accumulate at endosomes upon serum starvation, LAPTM4B knockdown reduced the endosomal localization of c-Met, but not of FGFR2 (Figures S3G and S3H) . Interestingly, whereas c-Met localization appears to be impacted by LAPTM4B, c-Met was not required for autophagy initiation (Figures S1C-S1E).
To further explore LAPTM4B regulation of EGFR endosome accumulation, a biotinylation assay was used to quantify the amount of cell-surface EGFR. This demonstrated that although the total EGFR level was reduced in LAPTM4B knockdown cells, the level of EGFR at the cell surface was not affected ( Figure 3G ), consistent with a specific loss of endosomal EGFR in LAPTM4B knockdown cells. This indicates that LAPTM4B mediates endosomal EGFR accumulation by stabilizing inactive EGFR at endosomes. Likewise, inactive EGFR also stabilizes LAPTM4B at endosomes, as knockdown of EGFR caused a loss of endosomal LAPTM4B staining, and re-expression of either WT or KD EGFR rescued LAPTM4B staining at endosomes ( Figure 3H) .
Importantly, the endosomal localization of EGFR or LAPTM4B is not dependent on Hrs or TSG101 ( Figure S3I ), both of which are essential for the ESCRT-mediated EGFR intraluminal sorting upon ligand stimulation (Sorkin and Goh, 2008) . This indicates that the pathway-mediating accumulation of inactive EGFR at LAPTM4B-positive endosomes is different from that for ligand stimulated EGFR endosomal sorting.
LAPTM4B Is Required for Basal and Serum Starvation-Induced Autophagy
The data suggest that EGFR-dependent autophagy initiation may be linked to LAPTM4B-mediated EGFR endosomal localization. To determine if LAPTM4B is required for autophagy, different siRNAs were used to knockdown LAPTM4B, and LC3-II turnover was quantified. Both LAPTM4B siRNAs knocked down LAPTM4B expression and inhibited basal autophagic flux ( Figures 4A-4C ). The chloroquine-induced accumulation of endogenous LC3 puncta was also strongly inhibited in LAPTM4B siRNA-treated cells ( Figures 4D and 4E ), phenocopying that of EGFR knockdown. Similarly, starvation-induced formation of the GFP-LC3 puncta was markedly decreased upon loss of (F) Quantification of the relative amount of endosomal EGFR staining in cells cultured in normal medium or serum-free medium (STV) normalized to the amount of endosomal EGFR staining in cells in serum-free medium plus EGF (100 ng/ml, 15 min); mean + SD, n = 3, ***p < 0.001. DAPI was used to stain the nuclei; pEGFR, phosphor-EGFR (Y1068). Bar, 10 mm. See also Figure S2 . Figures 4F and 4G) . Consistently, ectopic expression of LAPTM4B increased LC3-II turnover ( Figures S4A and S4B) , as well as basal GFP-LC3 puncta formation ( Figure S4C) , and re-expression of siRNA-resistant LAPTM4B rescued starvation-induced GFP-LC3 puncta formation in LAPTM4B knockdown cells ( Figure S4D ). Significantly, knockdown of EGFR and LAPTM4B together did not further inhibit LC3-II turnover compared to the single knockdown of either protein ( Figures  S4E and S4F) , suggesting that LAPTM4B and EGFR function in the same pathway.
LAPTM4B (
To explore if EGFR and LAPTM4B have mechanisms independent of each other for autophagy initiation, we examined autophagic turnover in cells with knockdown of one protein and overexpression of the other. Interestingly, overexpression of EGFR largely rescued autophagy in LAPTM4B knockdown cells ( Figures S4G and S4H ), whereas overexpression of LAPTM4B weakly, if at all, rescued autophagy in EGFR knockdown cells ( Figures S4I and S4J ). This suggests that LAPTM4B is a cofactor for EGFR-driven autophagy initiation.
Inactive EGFR and LAPTM4B Interact with the Exocyst for Autophagy Initiation
The data indicate that serum starvation promotes the assembly of an endosomal EGFR-LAPTM4B complex that regulates autophagy initiation. Recently, exocyst complexes have been implicated in starvation-induced autophagy (Bodemann et al., 2011) . A proteomic screen demonstrated that exocyst subunits interact with the EGFR complex (Foerster et al., 2013) ; we therefore explored if LAPTM4B and inactive EGFR interact with exocyst complex to modulate autophagy. As shown in Figures 5A and 5B, LAPTM4B and EGFR interact with multiple subunits of the exocyst complex. Sec8 is a core subunit of the exocyst and in endogenous coimmunoprecipitation (coIP), Sec8 associated with LAPTM4B and EGFR ( Figure 5C ). Exo70 also interacted with LAPTM4B and EGFR and localized to subdomains of LAPTM4B-positive endosomes ( Figure 5D ), and a fraction of endosomes were positive for EGFR, LAPTM4B, and Exo70 ( Figure 5E ).
As LAPTM4B selectively interacts with inactive EGFR, we determined if exocyst subunits interact similarly. Strikingly, Sec5 interacted with EGFR-KD much more strongly than with EGFR-WT ( Figures 5F and 5H ). Sec6 and Sec8 also associated with EGFR-KD more strongly ( Figures 5G, 5H , and S5A), but Exo70 and Exo84 did not ( Figures 5H, S5B , and S5C), demonstrating that inactive EGFR selectively associates with the Sec5 exocyst subcomplex.
To determine if the Sec5 subcomplex modulates autophagy, Sec5 was knocked down, and this strongly inhibited basal LC3 turnover ( Figures 5I and 5J ) and serum starvation-induced GFP-LC3 puncta formation ( Figures 5K and 5L ), indicating that Sec5 is required for basal and serum starvation-induced autophagy initiation. This was unexpected as Sec5 has inhibitory roles in amino acid starvation-induced autophagy (Bodemann et al., 2011) . Sec6, Sec8, and Exo70 also interacted with LAPTM4B and EGFR ( Figures 5A and 5B) , and all were required for autophagic turnover in MDA-MB-231 cells (Figures S5D-S5F) .
EGFR, LAPTM4B, and Sec5 Regulate Rubicon Disassociation from the Beclin 1 Complex Beclin 1 is a core subunit of the autophagy initiation complex involved in phagophore formation (He and Levine, 2010) . To investigate how inactive EGFR may modulate the Beclin 1 complex, changes in the Beclin 1 interactome (He and Levine, 2010) upon serum starvation were explored. Although serum starvation-induced strong autophagosome formation and autophagic flux in cells ( Figures 1A and S1H) , only the association between Beclin 1 and the autophagy inhibitor Rubicon was reduced, whereas the Beclin 1 association with VPS34 or ATG14 was not affected by serum starvation (Figures 6A and 6E) . Importantly, serum starvation strongly stimulated autophagy in control cells, but in Rubicon knockdown cells, basal autophagy is dramatically enhanced, and serum starvation does not further induce autophagy ( Figure S6 ), signifying that the disassociation of Rubicon from Beclin 1 is a major mechanism for serum starvation induced autophagy. EGFR, LAPTM4B, and Sec5 appear to have a collaborative role in autophagy initiation, as loss of any of these components blocked autophagy (Figures 1, 4 , and 5) and inhibited Rubicon disassociation from Beclin 1 (Figures 6B-6E) .
Rubicon strongly and selectively associates with EGFR-KD ( Figure 6F ), and consistently, serum starvation significantly enhanced the coIP of EGFR with overexpressed or endogenous Rubicon ( Figures 6G and 6H ), suggesting that inactive EGFR regulates autophagy by interacting with Rubicon. To determine if the (E) LAPTM4B is required for the endosomal accumulation of endogenous EGFR. MDA-MB-231 cells were treated with control or LAPTM4B siRNA, and after 48 hr, the siRNA-resistant LAPTM4B was re-expressed via transient transfection. Cells were serum starved and fixed for costaining of LAPTM4B (red) and EGFR (green). (F) Ectopically expressed wild-type (WT) and kinase-dead (KD) EGFR depend on LAPTM4B for endosomal accumulation. MDA-MB-231 cells stably expressing C terminally Flag-tagged EGFR-WT or -KD were treated with control or LAPTM4B siRNA, serum starved, and fixed for costaining of Flag (green) and endogenous LAPTM4B (red). (G) Control and LAPTM4B knockdown cells were surface biotinylated, and surface and total EGFR levels were analyzed by western blot (top left). Quantification of total EGFR levels (top right), cell-surface EGFR levels (bottom left), and the relative amounts of cell-surface EGFR (bottom right) in serum-starved control and LAPTM4B knockdown cells; mean + SD, n = 3; ***p < 0.001; ns, not significant. (H) Inactive EGFR stabilizes endosomal LAPTM4B. MDA-MB-231 cells were transfected with control or EGFR siRNA, and after 48 hr cells, they were transfected with empty vector (EV) or siRNA-resistant EGFR-WT or -KD and starved overnight, followed by fixing and costaining of EGFR (green) and LAPTM4B (red). WCL, whole-cell lysate; STV, serum starvation. Bar, 10 mm. DAPI was used to stain the nuclei. See also Figure S3 . EGFR C-tail (EGFR-CT) could modulate the Rubicon-Beclin 1 interaction in vitro, the Beclin 1 complex was purified by immunoprecipitation (IP) and incubated with purified glutathione S-transferase (GST) or EGFR-CT. As shown in Figures 6I and 6J, incubation with EGFR-CT efficiently disassociated Rubicon from Beclin 1 in vitro. The EGFR-CT lacks the kinase domain and is not phosphorylated, consistent with the concept that the inactive EGFR functions as a nonphosphorylated receptor in autophagy initiation and removes Rubicon from the Beclin 1 complex.
LAPTM4B is overexpressed in most epithelial cancers, and increased LAPTM4B expression enhanced the EGFR interaction with Rubicon and Sec5 ( Figure 6K ). Sec5 has been shown to associate with Rubicon (Bodemann et al., 2011) , and the knockdown of either LAPTM4B or Sec5 diminished the Rubicon interaction with EGFR ( Figures 6L and 6M ), indicating that LAPTM4B and Sec5 facilitate the Rubicon interaction with inactive EGFR. Thus, the endosomal inactive EGFR, with LAPTM4B and Sec5, Figure 3E , some EGFR intracellular puncta were observed here in LAPTM4B knockdown cells because of chloroquine treatment that blocked basal EGFR lysosomal degradation. Boxes are selected regions for magnified view. (E) Quantification of the number of LC3 puncta in (D); mean + SD, n = 3, ***p < 0.001. (F) Knockdown of LAPTM4B causes a loss of serum starvation-induced EGFP-LC3 puncta formation. MDA-MB-231 cells stably expressing low levels of EGFP-LC3 as described in Figure 1H were treated with control or LAPTM4B siRNA and serum starved or not before fixing for microscopy. (G) Quantification of the number of EGFP-LC3 puncta in (F) ; mean + SD, n = 3; ns, not significant; ***p < 0.001. Bar, 10 mm. DAPI was used to stain the nuclei. See also Figure S4. promotes disassociation of Rubicon from the Beclin 1 complex, which in turn initiates autophagy.
Erlotinib and Gefitinib Induce a Sec5-Dependent Role for Inactive EGFR in Autophagy Initiation
The EGFR TKIs erlotinib and gefitinib induce autophagy in multiple cancer cell lines, and the underlying mechanisms have been linked to the inhibition of the downstream PI3K/AKT/mTOR pathway and/or the inhibition of EGFR-mediated Beclin 1 phosphorylation (Dragowska et al., 2013; Jutten and Rouschop, 2014; Sobhakumari et al., 2013; Wei et al., 2013) . The role for inactive EGFR in autophagy initiation suggests that EGFR TKIs may induce a direct role for EGFR in autophagy. At clinically relevant concentrations (Baselga et al., 2002; Soulieres et al., 2004) , erlotinib or gefitinib stimulated autophagic activity comparable to that induced by serum starvation or rapamycin ( Figures 7A, S7A, and S7B) . Further, TKI-induced autophagy is EGFR dependent as loss of EGFR strongly suppressed gefitinib-induced autophagy ( Figures  7B and 7C) . TKIs downregulated phosphorylation of EGFR, but not of Akt ( Figure 7D ), consistent with a direct role for inactive EGFR, but not for Akt/mTOR inactivation, in the EGFR TKIinduced autophagy.
As erlotinib and gefitinib inhibit EGFR kinase activity, we investigated whether the EGFR-LAPTM4B-Sec5 pathway is required for autophagy initiation. Erlotinib and gefitinib inhibited the interaction between EGFR and LAPTM4B ( Figures 7E and 7I ) but still stimulated accumulation of EGFR at endosomes ( Figures  7F and S7C ), similar to serum starvation (Figure 2) . The EGFR interactions with Sec5, Sec6, and Rubicon were all enhanced by erlotinib or gefitinib ( Figures 7G-7I and S7D) . As with serum starvation, erlotinib or gefitinib also promoted Rubicon disassociation from the Beclin 1 complex (Figure 7J ), indicating that erlotinib and gefitinib induce a LAPTM4B-independent role for EGFR in Rubicon regulation. Finally and consistently, whereas Sec5 and LAPTM4B were required for basal autophagy ( Figures  7K and 7L, left) , loss of Sec5, but not of LAPTM4B, inhibited the gefitinib-(or erlotinib-; not shown) stimulated LC3-II turnover ( Figures 7K and 7L, right) . Together, these results reveal that the EGFR TKIs, erlotinib and gefitinib, stimulate a direct role for inactive EGFR in autophagy initiation that is dependent on Sec5 but is independent of LAPTM4B.
Together, the data suggest a model that serum starvation induces LAPTM4B-dependent EGFR accumulation at endosomes, where inactive EGFR synergizes with LAPTM4B and Sec5 in stimulating autophagy initiation independently of its tyrosine kinase activity by facilitating the disassociation of Rubicon from Beclin 1 (Figure 7M, top) . Similarly, EGFR TKIs induce LAPTM4B-independent accumulation of EGFR at endosomes, where EGFR associates with Sec5 and Rubicon to release Beclin 1 for autophagy initiation ( Figure 7M, bottom) .
DISCUSSION
Autophagy is activated in many cancers and facilitates cancer cell survival in stressed conditions (Brech et al., 2009; White, 2012) . EGFR plays crucial roles in many epithelial cancers, and its signaling has been linked to prosurvival, proliferative, and prometastatic functions of cancer cells (Mendelsohn and Baselga, 2006) . There are multiple links of EGFR to autophagy: (1) EGFR signaling activates the PI3K/AKT/mTOR pathway that inhibits autophagy; (2) activated EGFR directly phosphorylates and inhibits Beclin 1, a key component in autophagy initiation; and (3) EGFR TKIs upregulate autophagy in many cancer cells (Jutten and Rouschop, 2014; Li and Fan, 2010; Wei et al., 2013) . These studies all support a role for EGFR signaling in autophagy suppression.
Our data reveal a direct and unexpected role for inactive EGFR in autophagy initiation. Upon serum starvation, inactive EGFR forms a complex with LAPTM4B at endosomes, where it recruits the Sec5 exocyst subcomplex. This EGFR complex binds the autophagy inhibitor Rubicon, resulting in its disassociation from Beclin 1, releasing the Rubicon-free Beclin 1 complex to initiate autophagy ( Figure 7M, top) . These results establish the concept that whereas in nutrient-rich conditions activated EGFR suppresses autophagy and promotes cancer cell proliferation and survival through agonist stimulated EGFR signaling, in metabolically stressed conditions inactive EGFR alternatively facilitates cancer cell survival by activating autophagy. Consistent with our findings, kinase-independent roles for EGFR in cancer cell survival have been reported (Coker et al., 1994; Ewald et al., 2003; Weihua et al., 2008) , and cancer cells expressing EGFR have been shown to depend on autophagy for survival and growth (Jutten et al., 2013; Jutten and Rouschop, 2014; Sakuma et al., 2013) .
In clinical treatments, the EGFR TKIs erlotinib and gefitinib are effective in non-small-cell lung cancers (NSCLCs) that have activating mutations in EGFR, but show no effects in most solid tumors with WT EGFR (Mendelsohn and Baselga, 2006; Paez et al., 2004) . Recent studies have shown that treatment with EGFR TKIs increased autophagy with cytoprotective effects in many cancer cells (Dragowska et al., 2013; Eimer et al., 2011; Gorzalczany et al., 2011; Han et al., 2011; Jutten and Rouschop, 2014; Li et al., 2013; Sakuma et al., 2013; Sobhakumari et al., 2013; Zou et al., 2013) . EGFR TKIs activate autophagy by blocking the role for active EGFR in autophagy suppression in lung cancer cells with activating EGFR mutations (Wei et al., 2013) , but the mechanism by which the EGFR TKIs induce autophagy in cancer cells with WT EGFR was not defined. We show that EGFR TKIs induce a direct role for inactivated EGFR in autophagy initiation. EGFR TKIs mimic serum starvation and trigger endosomal accumulation of inactive EGFR that gains enhanced interaction with the Sec5 exocyst subcomplex and Rubicon, releasing Beclin 1 to initiate autophagy ( Figure 7M, bottom) . Thus, though EGFR TKIs block the cellular functions mediated by EGFR kinase signaling, they activate a role for inactive EGFR in autophagy that could potentially provide a survival advantage and TKI resistance in WT EGFR-expressing cancers. In fact, there is in vitro and in vivo evidence that cotargeting EGFR and autophagy is a promising strategy to overcome TKI resistance of cancer cells with WT EGFR, even when these cancer cells carry a different oncogenic factor like K-Ras or p53 (legend continued on next page) mutation (Choi et al., 2013; Dragowska et al., 2013; Jutten and Rouschop, 2014; Zou et al., 2013) . For example, while erlotinib or hydroxychloroquine (HCQ; a clinically available autophagy inhibitor) alone show no antitumor activity in xenografts derived from H460 NSCLC cells expressing WT EGFR but mutant KRas, combination of the two drugs resulted in dramatic inhibition of tumor growth . A recent clinical trial has confirmed the safety and tolerance for cotreatment of erlotinib with HCQ (Goldberg et al., 2012) , and additional trials combining HCQ with erlotinib or gefitinib are ongoing for the treatment of NSCLC.
EGFR and/or LAPTM4B are overexpressed in the majority of human cancers and contribute to cancer cell survival and proliferation (Kasper et al., 2005; Shao et al., 2003) . The results presented here highlight the roles for the oncoprotein LAPTM4B in EGFR-mediated cell survival functions. We have previously shown that LAPTM4B promotes active EGFR signaling by blocking EGF-stimulated EGFR intraluminal sorting and lysosomal degradation (X.T., Y.S., N.T., Y. Liao, A.C. Hedman, and R.A.A., unpublished data). In the EGF-stimulated condition, LAPTM4B has a weak interaction with EGFR, but it inhibits the function of Hrs, a key subunit of the endosomal sorting complex required for transport-0 (ESCRT-0), through enhancing the ubiquitination of Hrs by the E3 ubiquitin ligase Nedd4 (X.T., Y.S., N.T., Y. Liao, A.C. Hedman, and R.A.A., unpublished data). Here, we show that upon serum starvation, LAPTM4B senses EGFR inactivation at endosomes and selectively forms a complex with inactive EGFR to initiate autophagy. In both conditions, LAPTM4B facilitates the prosurvival functions of EGFR in cancer cells. The lack of a requirement for LAPTM4B in EGFR-TKIsinduced autophagy is not surprising, as LAPTM4B appears to be a cofactor for EGFR-driven autophagy, and the effects of LAPTM4B knockdown on autophagy can be largely compensated by EGFR overexpression (Figures S4G and S4H) . Importantly, in chemotherapies, LAPTM4B appears to increase drug resistance by multiple mechanisms (Li et al., 2010a (Li et al., , 2010c . Thus, although LAPTM4B is not required for the erlotinib/ gefitinib-induced EGFR functions in autophagy initiation, it may enhance EGFR-TKI resistance through other pathways. This supports LAPTM4B as a therapeutic target for EGFR-positive cancers or a combined target for anti-EGFR therapies.
Multivesicular endosomes (MVEs) and autophagosomes are closely related as in mammalian cells autophagosomes often fuse with endosomes to form amphisomes before the final formation of autolysosomes (Fader and Colombo, 2009; Lamb et al., 2013) . Therefore, endosomes have an established role in autophagosome maturation. Our results demonstrate that the endosome-localized inactive EGFR and LAPTM4B play pivotal roles in autophagy initiation. This emphasizes the importance of endosomes not only as canonical degradative compartments of the autophagosome content but also as signaling organelles that activate the autophagy pathway. The EGFRmediated Rubicon-Beclin 1 disassociation may occur at the endosomal surface, but the Beclin 1 complex functions in autophagosomal membrane nucleation at the endoplasmic reticulum (ER) (Hamasaki et al., 2013; Lamb et al., 2013) . This suggests that the phagophore initiation sites at ER are in close proximity to endosomal Beclin 1-releasing sites. In support of this, LC3 puncta were observed adjacent to EGFR-positive endosomes ( Figures 1D and 4D , top panels), suggesting that autophagosomes are formed at the ER close to EGFR-positive endosomes. Consistently, there are tight associations between the ER network and endosomes through ER-endosome contacts in mammalian cells (Eden et al., 2010; Friedman et al., 2013; Helle et al., 2013) . Although most studies have focused on the roles for ER, mitochondria and Golgi in phagophore initiation, the ER-endosome contact sites are positioned to play key roles. In this case, autophagosome maturation could be coupled, as autophagosomes would be formed close to endosomes.
In summary, this study identifies a key role for inactive EGFR in autophagy initiation in cells with WT EGFR gene in both serum starved and EGFR TKIs-treated cells. It provides insights into the mechanistic regulation of cancer cell survival by EGFR expression in metabolically stressed tumors and suggests a basis for EGFR TKI resistance in the treatments of tumors without EGFR mutations.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, Plasmids, siRNA, Antibodies, and Reagents MDA-MB-231, HeLa, A431, and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Corning) with 10% fetal bovine serum (FBS) (Invitrogen). Transfection of plasmids and siRNA oligonucleotides was carried out using Lipofectamine 2000 and Lipofectamine RNAiMax (Invitrogen), respectively, following the manufacturer's instructions. For serum starvation, cells were washed with DMEM twice and cultured in DMEM without FBS for the indicated time periods. A detailed description of reagents, DNA plasmids, antibody origins, siRNA sequences, and cell treatments is included in the Extended Experimental Procedures.
Immunofluorescence Microscopy
Immunostaining of tagged and endogenous proteins was performed using standard procedures. Cells on glass coverslips were washed, fixed, permeabilized, blocked, and stained with indicated antibodies. Cells were mounted using Vectashield and visualized with a Nikon TE2000-U microscope. Colocalization quantification was performed using the Coloc 2 plugin for Fiji (ImageJ) . See the Extended Experimental Procedures for details.
CoIP and Western Blotting Assays
Immunoprecipitation of indicated proteins was performed using nondenaturing cell extracts. Immunocomplex and whole-cell lysates were analyzed by SDS-PAGE, followed by immunoblotting with indicated antibodies. See the Extended Experimental Procedures for details. 
(legend continued on next page)
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